T1	intervention 23 57	palbociclib plus endocrine therapy
T2	location 61 75	North American
T3	total-participants 543 546	267
T4	total-participants 593 596	240
T5	eligibility 706 773	treatment-naïve postmenopausal patients with advanced breast cancer
T6	control 890 912	placebo plus letrozole
T7	outcome 1224 1256	median progression-free survival
T8	iv-cont-median 1329 1333	25.4
T9	cv-cont-median 1337 1348	13.7 months
T12	iv-cont-median 1411 1414	9.9
T13	cv-cont-median 1418 1428	3.5 months
T16	outcome 1505 1536	clinical benefit response rates
T17	outcome 1482 1500	Objective response
T18	outcome 1682 1705	median overall survival
T19	iv-cont-median 1733 1737	32.0
T20	cv-cont-median 1741 1752	24.7 months
T10	eligibility 927 977	patients who progressed on prior endocrine therapy
